Vimarsana
Biggest News Aggregation in the World

Page 20 - Over Time News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Over Time. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Over Time Today - Breaking & Trending Today

NDC, PSE see inflow of investments with Maharlika Investment Fund - Vimarsana News

NDC, PSE see inflow of investments with Maharlika Investment Fund

SOVEREIGN WEALTH FUND.President Ferdinand R. Marcos Jr. makes a soft launching of the Philippines' sovereign wealth fund (SWF) at the Country Strategy Dialogue during the World Economic Forum in Davos, Switzerland on Tuesday (Jan. 17, 2023). Marcos said the SWF, known as Maharlika Investment Fund, is already in the pipeline.(Photo courtesy of Office of the President) MANILA-Both the National Development Company (NDC) and the Philippine Stocks Exchange on Monday assured senators of investments that would come in once the country establishes the proposed Maharlika Investment Fund (MIF). Duri...

EQS-News: Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023 - Vimarsana News

EQS-News: Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023

Issuer: Immunic, Inc. / Key word(s): Conference/Study Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023 22.02.2023 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immun...

Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023 - Vimarsana News

Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...

EQS-News: Immunic, Inc.: Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023 - Vimarsana News

EQS-News: Immunic, Inc.: Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023

Issuer: Immunic, Inc. / Key word(s): Conference/Study Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023

Thermon Group Holdings, Inc.: Thermon Reports Third Quarter Fiscal 2023 Results - Vimarsana News

Thermon Group Holdings, Inc.: Thermon Reports Third Quarter Fiscal 2023 Results

Revenue Up 21%; Raising Full Year GuidanceAUSTIN, TX / ACCESSWIRE / February 2, 2023 / Thermon Group Holdings, Inc. (NYSE:THR) ("Thermon"), a global leader in industrial process heating solutions, today